- Current report filing (8-K)
January 28 2010 - 4:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
January 28, 2010
(
January 26, 2010
)
Nyer Medical Group,
Inc.
(Exact name of registrant as specified
in its charter)
Commission File
Number: 000-20175
|
|
|
Florida
|
|
01-0469607
|
(State or other
jurisdiction
of
incorporation)
|
|
(IRS Employer
Identification
No.)
|
13 Water Street, Holliston, MA
01746
(Address of principal executive
offices, including zip code)
(508) 429-8506
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
¨
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
3.01
Notice of
Delisting or Failure to Satisfy a Continued Listing Rule or Standard: Transfer
of Listing.
On
January 26, 2010, Nyer Medical Group, Inc. (the “Company”) notified the NASDAQ
Stock Market (“NASDAQ”) of its intent to voluntarily delist its securities by
filing a Form 25 with the Securities and Exchange Commission on or about
February 8, 2010. The Company anticipates that the delisting will be
effective 10 days after the date of filing of the Form 25, on or about February
18, 2010. In connection with the delisting, the Company requested
that NASDAQ suspend trading effective at the close of business on February 1,
2010. The Board of Directors of the Company approved the voluntary
delisting of the securities on October 21, 2009. Upon delisting from
the Exchange, the Company securities will be added to the over-the-counter
market.
WARNING
CONCERNING FORWARD LOOKING STATEMENTS
This
report contains forward looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal securities
laws. These forward looking statements are based on the Company’s
present expectations, but these statements and the implications of these
statements are not guaranteed to occur and may not occur for various
reason. For example:
This
report states that the Company expects to delist its securities on or about
February 18, 2010. However, the delisting is contingent on the
closing of the transactions described in the Company’s Proxy Statement dated
December 17, 2009 (the “Transactions”). The Transactions are subject
to various conditions and contingencies as are customary in purchase agreements
and plans of dissolution in the United States. If these conditions
are not satisfied or the specified contingencies occur, the Transactions may be
delayed or may not be completed and the Company may not delist its
securities.
For these
reasons, among others, you should not place undue reliance upon forward looking
statements.
Except as
required by law, the Company does not assume any obligations to update any
forward looking statements as a result of new information, changed
circumstances, future events or otherwise.
Signatures
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
Nyer Medical Group,
Inc.
|
|
|
|
|
|
|
Date:
January 28,
2010
|
|
By:
|
|
|
|
|
|
|
Mark A.
Dumouchel
|
|
|
|
|
President and Chief Executive
Officer
|
Nyer Medical (NASDAQ:NYER)
Historical Stock Chart
From Feb 2025 to Mar 2025
Nyer Medical (NASDAQ:NYER)
Historical Stock Chart
From Mar 2024 to Mar 2025